ABSTRACT
Background: CD39 and CD73 are two novel cell surface markers of CD25$^{\text{high}}$Foxp3$^{+}$ regulatory T-cells (Tregs). Concordant expression of these two ectoenzymes not only discriminate Tregs from other cell populations, but also generates pericellular adenosine, which has been reported to suppress proliferation of activated T effector (Teff) cells. Because it is currently unclear whether human ectoenzymes (CD39/CD73) are involved in the impaired suppressive activity of Tregs in psoriasis, we examined the frequencies and phenotypes of CD39/CD73 expressing Tregs and related receptor adenosine receptor 2A ($\text{A}_{2\text{A}}\text{R}$) expressing Teff in peripheral blood of patients with different types of psoriasis.

Methods: Peripheral blood mononuclear cells (PBMC) were prepared from patients with three different types of psoriasis (psoriasis vulgaris, pustular psoriasis and erythrodermic psoriasis). CD4$^+$ cells were separated from PBMC by negative selection on midiMACS columns, and the frequencies and phenotypes of CD39/CD73-expressing Tregs and related receptor adenosine receptor 2A ($\text{A}_{2\text{A}}\text{R}$) in peripheral blood of patients with different types of psoriasis.

Results: The expression of single CD73$^+$ Tregs was markedly reduced (approximately 50%) in psoriasis vulgaris, compared to normal controls. In pustular psoriasis, the mean numbers of CD39$^+$ Tregs and $\text{A}_{2\text{A}}\text{R}^+$ Teff was significantly lower than in normal controls. Among three different types of psoriasis, CD39 expression was strikingly reduced in the blood Treg population of pustular psoriasis patients. Decreased CD73$^+$ Tregs levels were observed in psoriasis vulgaris compared to pustular psoriasis and erythrodermic psoriasis.

Conclusions: The differences in the expression of CD39$^-$ and CD75$^-$ Tregs may be a factor in the pathogenesis of psoriasis.

Key words: $\text{A}_{2\text{A}}\text{R}$, CD39, CD73, ectoenzymes, psoriasis, Tregs.

INTRODUCTION

CD4$^+$CD25$^{\text{high}}$Foxp3$^+$ regulatory T-cells (Tregs) are believed to be the key lymphocyte sub-population in the maintenance of immunological self-tolerance by
suppressing immune responses. The study of Su and colleagues focused on their specific surface markers, which have now been expanded to include CC chemokine receptor type 4 (CCR4), CCR5, CTLA-4 and CD127, allowing a better understanding of the immunosuppressive mechanisms of Treg cells.

CD59/ectonucleoside triphosphate diphosphohydrolase and CD75/ecto-5'-nucleotidase are two novel cell surface markers identified in mouse Tregs. The concordant expression of these two ectoenzymes not only differentiates Tregs from other cell populations but also generates pericellular adenosine. Adenosine generation and its consequent effects, mediated by adenosine 2a receptors (A2aR) on T effector cells (Teff), play a critical role in the blockade of the activated Teff proliferation and pro-inflammatory cytokine secretion (Fig. 1). Conversion of extracellular adenosine triphosphate to adenosine by pericellular adenosinergic pathway (CD59, CD75 and A2AR) has already been demonstrated as a key anti-inflammatory mechanism of Tregs with intriguing implications in immune-mediated human diseases such as, multiple sclerosis, squamous cell carcinoma and arthritis. Psoriasis is a common, chronic autoimmune disease of the skin that has serious effects on the patient's physical and mental health. The pathogenesis of psoriasis is complex and involves genetic, immunological and even neurological factors. It is now widely accepted that a dysregulated T-cell response, in which the activity of pathogenic effector T-cells is inadequately controlled by psoriatic regulatory T cells. However, the mechanisms underlying psoriatic Treg dysfunction have not been completely elucidated. In the current study, we examined the proportion of ectoenzymes CD59/CD75 and A2AR expression by peripheral blood Tregs in different types of psoriasis. Given the inhibitory function of pericellular adenosine against Teff, the change of co-expression of CD75 and/or CD59 may participate in the attenuated suppression capacity of peripheral blood Tregs in psoriatic patients.

**MATERIALS AND METHODS**

**Participants**

A total of 50 patients with psoriasis (including 10 each with psoriasis vulgaris (PV), pustular psoriasis (PP) and erythrodermic psoriasis [PE]) and 10 age-matched healthy volunteers were enrolled in this study (Table 1). The protocols involving human subjects were approved by the institutional review boards of Huashan Hospital, Fudan University, China and the University Hospitals of Cleveland, Case Western Reserve University, Ohio, USA. Informed consent was obtained from all participants. A medication-free period of at least 1 month for oral drugs was required in all groups, and psoriatic patients refrained from using topical medications or phototherapy for at least 2 weeks before the blood collection procedures. The different types of psoriasis were defined mainly according to their clinical characteristics. The psoriasis area and severity index (PASI) was used to assess the severity of PV and the scores give a range from 0 to 72. For PP we used the method reported by Ohkawara, which evaluated the disease based on erythema, pustules, confluent pustules and enanthema.

**Cell isolation**

Human PBMC was prepared from heparinised venous blood by Histopaque (Sigma-Aldrich, St Louis, MO, USA) density gradient centrifugation according to the manufacturer's directions. CD4+ cells were separated from PBMC according to the manufacturer's instructions. The purity of the enriched CD4+ T-cells exceeded 95% (Fig. 2).

**Flow cytometry analysis**

CD4+ T-cells were incubated with the appropriate monoclonal antibodies (mAb) first to identify cell surface
Table 1 Clinical and immunological profile of the studied patients

| Sex | Age, years | Disease duration, years | Score | CD39+/Treg (%) | CD73+/Treg (%) |
|-----|------------|-------------------------|-------|---------------|---------------|
| M   | 36         | 9                       | 22.0  | 47.7          | 71.3          |
| M   | 32         | 8                       | 26.2  | 52.1          | 7.5           |
| F   | 55         | 7                       | 50.2  | 69.5          | 4.7           |
| M   | 45         | 5                       | 20.6  | 64.1          | 6             |
| F   | 28         | 9                       | 25.4  | 18.7          | 8.9           |
| F   | 30         | 12                      | 35.7  | 22.5          | 5.9           |
| M   | 55         | 5                       | 42.1  | 45.3          | 3.9           |
| F   | 45         | 18                      | 20.0  | 68.5          | 8.2           |
| M   | 46         | 9                       | 18.5  | 50.4          | 7.5           |
| M   | 25         | 10                      | 25.5  | 54            | 6.3           |
| Mean ± SD | 55.1 ± 4     | 9.2 ± 2                  | 45.5 ± 10 | 7.0 ± 1.5   |               |

Erythrodermic psoriasis (PE, n = 10)

| Sex | Age, years | Disease duration, years | Score | CD39+/Treg (%) | CD73+/Treg (%) |
|-----|------------|-------------------------|-------|---------------|---------------|
| M   | 50         | 10                      | –     | 75.7          | 7.4           |
| F   | 59         | 12                      | –     | 68.1          | 9.0           |
| F   | 62         | 20                      | –     | 84.5          | 12.7          |
| F   | 56         | 9                       | –     | 28.4          | 14.5          |
| M   | 45         | 17                      | –     | 20.5          | 15.3          |
| M   | 59         | 20                      | –     | 92.7          | 10.2          |
| M   | 45         | 10                      | –     | 96.4          | 14.5          |
| M   | 58         | 8                       | –     | 5.4           | 14.3          |
| M   | 59         | 11                      | –     | 59.5          | 15.2          |
| F   | 49         | 18                      | –     | 65.1          | 10.9          |
| Mean ± SD | 44 ± 5.8     | 15.5 ± 2.7                | 59.4 ± 18 | 12.2 ± 1.5   |               |

Pustular psoriasis (PP, n = 10)

| Sex | Age, years | Disease duration, years | Score | CD39+/Treg (%) | CD73+/Treg (%) |
|-----|------------|-------------------------|-------|---------------|---------------|
| F   | 55         | 8                       | 4     | 62.2          | 11.0          |
| F   | 59         | 10                      | 5     | 27.1          | 10.7          |
| M   | 48         | 7                       | 5     | 21.8          | 14.5          |
| F   | 59         | 15                      | 4     | 55.0          | 12.1          |
| F   | 40         | 15                      | 4     | 17.7          | 10.0          |
| M   | 47         | 10                      | 6     | 18.9          | 14.6          |
| M   | 57         | 7                       | 5     | 51.2          | 15.2          |
| M   | 55         | 11                      | 5     | 10.4          | 11.1          |
| F   | 52         | 12                      | 5     | 25.4          | 13.8          |
| F   | 50         | 9                       | 5     | 55.2          | 11.8          |
| Mean ± SD | 44.2 ± 4.6     | 10.2 ± 1.5                 | 50.5 ± 9.3 | 12.5 ± 1.1   |               |

Controls (n = 10)

| Sex | Age, years | Disease duration, years | Score | CD39+/Treg (%) | CD73+/Treg (%) |
|-----|------------|-------------------------|-------|---------------|---------------|
| Mean ± SD | 58          | –                       | 58.4 ± 14 | 15.2 ± 3.5   |               |

markers, followed by fixation in fixation/permeabilisation buffer for intracellular marker identification. The samples were analyzed using a BD LSR flow cytometer (Becton Dickinson, San Jose, CA, USA). The following mAb were used: phycoerythrin (PE) antihuman CD75 (clone AD2; BD Biosciences), allophycocyanin (APC) antihuman CD25 (clone 2A5; BD Biosciences), fluorescein isothiocyanate (FITC) antihuman Foxp3 (clone PCH101 set; eBioscience, San Diego, CA, USA), phycoerythrin-Cy7 antihuman CD39 (clone eBioA1; San Diego, CA, USA), human recombinant adenosine receptor 2A (Lifespan Biosciences, Seattle, WA, USA) and Pacific orange goat anti-mouse immunoglobulin G antibody for second antibody (Invitrogen, San Diego, CA, USA).

For intracellular Foxp3 protein staining, CD4+ T-cells were first stained with surface mAb (anti-CD25-APC, anti-CD75-PE, anti-CD39-PE-Cy7 and A2A R mouse anti-human mAb), and then were fixed and permeabilised using the Foxp3 Staining Buffer Set (eBioscience). Subsequently, the cells were stained with anti-Foxp3-FITC mAb, according to the manufacturer’s instructions (eBioscience).

CD25[high] was identified based on the median fluorescence intensity (MFI) >120 for CD25 expression on CD4+ T-cells.

Cells with a MFI < 120 were set as CD25[low]. Flow cytometry data was analyzed using WinList (Verity Software House, Topsham ME, USA) software.

Statistical analysis

Data are expressed as mean ± SD, and P < 0.05 was considered statistically significant. Statistical significance between different types of psoriasis was determined by one-way ANOVA with a Bonferroni post hoc test. Student’s t-test was used for the comparison of two different samples. Correlations were calculated using the nonparametric Spearman’s rank correlation test.

RESULTS

CD59, CD73 expression levels on CD4+CD25[high]Foxp3+ Tregs from peripheral blood in healthy controls

On the basis of the CD25 expression level, human CD4+ T-cells can be divided into three: CD25[high], CD25[medium] and CD25[low] cells. Combined with Foxp3, flow cytometry analysis revealed that the CD25[high]Foxp3+ Tregs was highly enriched in CD39+ (58 ± 14%, P < 0.01, n = 10) relative to CD25[medium]Foxp3+ and CD25[low]Foxp3+ cells (8 ± 2 and 7 ± 1%, respectively). CD73 surface expression was low in Tregs (15 ± 4%, P < 0.05). This is in contrast to murine Tregs, which are reported to express high levels of CD73.5 Double staining of CD25[high]Foxp3+ Treg subsets revealed that only a very small portion of cells were CD59+CD73+, whereas there was almost no expression on CD25[medium]Foxp3+ and CD25[low]Foxp3+ (6 ± 1%, P < 0.01; Fig. 5a,b).

CD59, CD73 expression levels on CD4+CD25[high]Foxp3+ Tregs from peripheral blood in different types of psoriasis

The expression of CD73 was significantly decreased in PP patient Tregs (7.0 ± 2%, n = 10) compared with healthy controls (15 ± 4%, n = 10), P < 0.01 (Fig. 4a,b). The double positive expression of CD59 and CD73 on Tregs was also decreased in PV (P < 0.05). The level of CD59 expressed by CD25[high]Foxp3+ Tregs was significantly lower in PP patients than in normal controls (30 ± 9% vs 60 ± 14%, P < 0.01, Fig. 4b). There was no difference in expression between PE patients and controls. There was no statistically significant correlation between the percentage of CD73 Tregs and the severity of PV, and between CD39 Tregs and the severity of pustular psoriasis (Fig. 4c, r² = 0.247 and 0.05602, respectively).

Furthermore, we compared the proportions of CD39+ and CD73+ Treg among different types of psoriasis. A significant
reduction of CD39+ Tregs was observed in PP patients [PV (45 ± 10%), PP (50 ± 9%), PE (50 ± 18%)] (Bonferroni P < 0.0001), while the number of CD73+ Tregs was significantly lower in PV patients than in PP and PE patients [PV (7 ± 1%), PP (12 ± 2%), PE (12 ± 1%); Bonferroni P < 0.0001].

A2AR expression level In CD4+CD25+ Teff cells in different types of psoriasis and healthy controls peripheral blood

Figure 5b shows the A2AR expression level in CD4+CD25+ Teff cells was reduced in PE and PP patients compared to PV patients and normal controls [PV (19 ± 4%), PP (5.95 ± 1%), PE (2.53 ± 1%); Bonferroni P < 0.0001]. No difference was observed in A2AR expression in CD4+CD25+ Teff cells between PV patients and normal control, PE and PP patients.

DISCUSSION

Treg-mediated immune suppression involves many molecular mechanisms. Ectonucleotidases CD59 and CD73 have been found to be expressed on the surface of murine and human Treg.20,21 Extracellular adenosine is a hydrolysis product of adenosine triphosphate cleaved in tandem by CD59 and CD75. In conjunction with the receptor expressed on Teff cells (A2AR), adenosine leads to the elevation of cyclic adenosine monophosphate (cAMP) levels, which plays a crucial role in immunosuppression (Fig. 1).5 Psoriatic CD4+CD25high Tregs are functionally deficient in suppressing effector T-cell proliferation.12–14 We have just published our findings on skin-infiltrating CD39+Foxp3+ and CD75+Foxp3+ in different psoriatic lesions. The relative reduced expressions of CD59 and CD75 in Foxp3+ Tregs may imply there is a different mechanism for Tregs function impairment.22 In the present study, we sought to assess the expression levels of CD59/CD75 specifically on peripheral blood Tregs involved in psoriatic pathology. There is no single surface marker that has been identified for Treg cells. Both Foxp3 and CD25 expression on Treg cell, have limitations. We therefore combined these two molecular markers to define Treg cells more accurately.23,24
Our data on the phenotypical analysis of ectoenzymes in Tregs in healthy controls show that nearly 60% of CD25^{high}Foxp3^{+} human Tregs were positive for CD39, which is consistent with other research findings.8,24 The surface expression of CD73, described as a characteristic surface marker of murine Treg,5 was observed in only a small proportion of human Treg (almost 13%). Since CD73 has a synergistic function with CD39, the unbalanced expression of these two molecules suggests that CD73 is readily shed from the surface of human lymphocytes.25

Flow cytometric analyses revealed that the proportion of CD75^{+} cells among CD25^{high}Foxp3^{+} Tregs in the blood of PV patients was markedly reduced (Fig. 3). However, we could not detect other changes in CD39^{+} Tregs or A2AR expression on effector T-cells in PV patients. Taken together, our data show that the production of extracellular adenosine monophosphate (AMP) adenosine is mediated by normal CD39 levels in Tregs, but the striking reduction in the number of CD75^{+} Tregs may ultimately affect extracellular adenosine generation. This, in turn, leads to a reduction in intracellular cAMP accumulation, which provides a possible mechanistic explanation for the dysfunction of the suppressive capacity of psoriatic Treg cells.

We observed strikingly reduced CD39 expression in the Tregs population and A_{2A}R levels on T effector cells of pustular psoriasis patients (Fig. 5b, 5b). Jenabian and colleagues26 reported that CD39^{+} Tregs suppress the interleukin-2 expression of activated CD4^{+} T-cells more efficiently than CD39^{-} Tregs, and the CD39^{+} Tregs appeared to be bona fide Tregs. Chemotaxis of neutrophils

Figure 5 The proportion of CD39 and CD75 expressing CD25^{high}Foxp3^{+} Tregs in peripheral blood of healthy controls. Expression levels of CD39 and CD75 on normal CD25^{high}Foxp3^{+} regulatory T-cells (Tregs; n = 10). (a) Histogram depicts CD4^{-} (negative bead selection) cells defined by CD25 and Foxp3. CD25^{high}Foxp3^{+} Tregs, CD25^{mid}Foxp3^{+} and CD25^{neg}Foxp3^{+} T-cells were gated and further analyzed for expression of CD39 and CD75. (b) CD4^{+}CD25^{high}Foxp3^{+} Tregs showed significantly higher expression levels of CD39 (P < 0.01) and lower proportion CD73 (P < 0.05) compared to CD25^{mid}Foxp3^{+} and CD25^{neg} pool. (*P < 0.05, **P < 0.01, Student’s t-test).
is the main reason for the formation of pustules, while inadequate activity of the CD39/CD73 axis has been associated with the uncontrolled activation of neutrophil chemotaxis. Significantly impaired CD39^Treg and A2AR^Teff levels in pustular patients (compared to normal controls, PV and PE patients) may be one of the reasons for the difference between pustular psoriasis lesions and other types of psoriasis.

Until now, there have been no published studies on peripheral blood Treg cells in pustular psoriasis. Further studies should address the Tregs function in pustular psoriasis and whether ectoenzyme CD39 is involved in the function's abnormalities.

Borsellino and colleagues were the first to report that patients with the remitting/relapsing form of multiple sclerosis had strikingly reduced numbers of CD39^Treg cells
in the blood, while there were no changes in the CD39+ Treg cell number after the treatment of immunomodulators or in a clinical remission state. Increased levels of CD39+ Treg were also correlated with poor prognosis in sepsis patients, which suggests that CD39+ Treg expression could be used as a prognostic biomarker. However, we could not detect a correlation between the severity of psoriasis patients (including PV and pustular psoriasis) and CD39/CD73 expression in Tregs.

Our research compared CD39 and CD73 expression levels in peripheral blood Tregs among three different types of psoriasis. A decreased CD39+ Tregs level was found in pustular psoriasis compared with PV and PE patients, which is consistent with the significant reduction of CD39+ Treg cells in pustular psoriasis lesions found in our previous study.

Future research requires an expansion in the number of study participants, further stratified according to their disease course (early stage, remitting/relapsing form and advanced stage) and functional assays of the capacity of these enzymes, which will widen our understanding of the role of ectoenzymes CD59 and CD75 and A2AR function in psoriatic Treg cells.

ACKNOWLEDGEMENTS

This study was supported by funding from National Natural Science Foundation of China, Grant no. 81502715 and by funding from the Science and Technology Commission of Shanghai Municipality, Grant no. 13JC1402502.

REFERENCES

1. Sakaguchi S, Sakaguchi N, Asano M et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2

© 2017 The Authors. Australasian Journal of Dermatology published by Wiley Publishing Asia Pty Ltd on behalf of The Australasian College of Dermatologists.
receptor alpha-chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 1995; 155: 1151–64.

2. Bach J-F. Regulatory T cells under scrutiny. Nat. Rev. Immunol. 2003; 5: 189–98.

3. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 2005; 6: 345–52.

4. Su H, Longhi MS, Wang P et al. Human CD4+CD25 (high) CD127 (low/neg) regulatory T cells. Methods Mol. Biol. 2012; 806: 287–99.

5. Deaglio S, Dwrey KM, Gao W et al. Adenosine generation catalyzed by CD59 and C D75 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 2007; 204: 1257–65.

6. Sitkovsky M, Lukashev D, Deaglio S et al. Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells. Br. J. Pharmacol. 2008; 155 (Suppl. 1): S457–64.

7. Haskó G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. Trends Immunol. 2004; 25: 33–9.

8. Borsellino G, Kleineveldt M, Di Mitri D et al. Expression of ectonucleotidase CD59 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007; 110: 1225–32.

9. Mandapathil M, Szczepanski MJ, Szajnik M et al. Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin. Cancer Res. 2009; 15: 6348–57.

10. Rissiek A, Baumann I, Cuapio A et al. The expression of CD59 on regulatory T cells is genetically driven and further upregulated at sites of inflammation. J. Autoimmun. 2015; 58: 12–20.

11. Schon MP, Boehncke WH. Psoriasis. N. Engl. J. Med. 2005; 552: 1899–912.

12. Sugiyama H, Gyulai R, Toichi E et al. Dysfunctional blood and target tissue CD4+CD25(high) regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J. Immunol. 2005; 174: 164–73.

13. Goodman WA, Levine AD, Massari JV et al. IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J. Immunol. 2009; 183: 5170–6.

14. Huang Q, Han L, Fang X et al. A study of the function of CD4+CD25+ regulatory T cells in peripheral blood of patients with psoriasis vulgaris. Zhonghua Pi Fu Bing Xue Za Zhi 2010; 45: 251–5 (Chinese).